Dalan Animal Health has closed a $3 million SAFE financing round to accelerate the commercialization of its first-in-class shrimp vaccine and extend its Innate Immunity Platform into additional species, marking a significant step forward for the bioscience company following the successful launch of its honeybee vaccine. The round was backed by Good Growth Capital, Meach Cove Capital, and several global investors, highlighting increasing international interest in Dalan’s technology and next-phase product pipeline.
The seed capital will enable the company to advance its shrimp vaccine toward full commercial deployment, as global aquaculture faces mounting disease-related losses. Diseases such as White Spot Syndrome Virus cause up to $4 billion in damage annually, and the industry currently lacks a scalable prevention solution. Recent clinical trials have demonstrated the strong efficacy of Dalan’s vaccine against major shrimp pathogens, allowing the company to advance regulatory work, expand manufacturing, and prepare for market entry.
The financing also supports Dalan’s broader platform ambitions. Building on its pioneering work in honeybee and shrimp health, the company will explore new applications across poultry and additional aquaculture species, targeting markets where antibiotics remain heavily relied upon for disease control. Dalan’s Innate Immunity Platform is based on conserved pattern recognition receptors present across all animals, a feature that allows for cross-species adaptation and positions the platform as a potentially transformative approach to disease prevention in global food production.
The investor group’s participation also brings new strategic guidance. Harris Komishane, General Partner at Meach Cove Capital, will join the company’s Board of Directors as an observer, contributing to commercialization efforts as Dalan scales its product roadmap.
The company’s European operations are gaining traction as well. Dalan Bio SL, the firm’s European subsidiary, has secured a €250,000 grant from the Spanish Ministry of Science’s Center for the Development of Industrial Technologies and Innovation to support Pan European surveillance of honeybee diseases. The grant strengthens the subsidiary’s research capabilities and supports Dalan’s international expansion strategy as it prepares for broader market adoption.
Together, the new financing and European grant underscore global interest in Dalan’s approach to disease prevention and its potential to reshape health management across multiple species.
KEY QUOTES:
“This funding round represents a pivotal moment as we advance from our proven success in honeybees to commercializing our groundbreaking shrimp vaccine. The participation of sophisticated global investors like Good Growth Capital and Meach Cove Capital validates both our immediate commercial opportunity in aquaculture and the broader potential of our Innate Immunity Platform to address disease prevention challenges across multiple species.”
Dr. Annette Kleiser, CEO and Founder of Dalan Animal Health
“We believe Dalan’s pioneering approach to protecting vital animal species through its cutting-edge vaccination technology is game changing.”
Harris Komishane, General Partner at Meach Cove Capital
“Dalan’s vaccine is already proving transformative in the protection of bees, critical to our food sources. Adding the shrimp vaccine, addressing the world’s largest seafood protein, is not only a huge market, but is proving Dalan’s platform technology is applicable to many species.”
Maureen Stancik Boyce, PhD, Founder and Managing Partner of Good Growth Capital
